The only variant with evidence level 1 that showed greater MAF in the MxGDAR/Encodat was NUDT15*3 (dMAF = 0.0452), a variant that may increase the risk of leukopenia or neutropenia in those individuals treated with purine compounds (Yang et al., 2014). This evidence concerns the gene NUDT15 and Decreased total leukocyte count.